Literature DB >> 35348983

Multicenter prospective observational study of fungal keratitis in Japan: analyses of in vitro susceptibility tests for combinations of drugs.

Keigo Kimura1, Yoshitsugu Inoue2, Seishi Asari1, Atsuko Sunada1, Yuichi Ohashi3, Yoshikazu Shimomura4, Chie Sotozono5, Hiroshi Hatano6, Masahiko Fukuda7, Hiroshi Eguchi8, Kaoru Araki-Sasaki9, Takashi Suzuki10, Saichi Hoshi11, Toru Tobe12, Takashi Yaguchi13, Koichi Makimura14.   

Abstract

PURPOSE: To determine the effects of a combination of two antifungal drugs against causative fungi of fungal keratitis in Japan. STUDY
DESIGN: Multicenter prospective observational study.
METHODS: Eighteen isolates of yeast-like fungi and 22 isolates of filamentous fungi collected by the Multicenter Prospective Observational Study of Fungal Keratitis in Japan were studied. Specially manufactured minimum inhibitory concentration (MIC) measurement plates were used to test the effectiveness of 10 combinations of two antifungal drugs against the isolates. The combinations were pimaricin (PMR) + voriconazole (VRCZ), PMR + fluconazole (FLCZ), PMR + miconazole (MCZ), PMR + micafungin (MCFG), VRCZ + FLCZ, VRCZ + MCZ, VRCZ + MCFG, VRCZ + amphotericin-B (AMPH-B), MCZ + FLCZ, and MCZ + MCFG. The checkerboard microdilution method was used, and the fractional inhibitory concentration (FIC) index was calculated based on the guidelines of The Clinical & Laboratory Standards Institute (CLSI).
RESULTS: In yeast-like fungi, additive effects were observed between PMR and MCFG in 77.8% of the isolates, and they were also observed between the azoles. Synergistic effects were observed on 11.1% of the isolates for MCZ and FLCZ. On the other hand, antagonistic effects were present between PMR and azoles with 88.9% between PMR and VRCZ, 72.2% between PMR and FLCZ, and 94.4% between PMR and MCZ. In filamentous fungi, additive effects were observed between PMR and MCFG in 40.9% of the isolates, and between VRCZ and MCZ in 40.9% of the isolates. Antagonistic effects were observed for PMR and the azoles.
CONCLUSIONS: The combination of drugs prescribed for fungal keratitis incurs a possibility of synergistic, additive, indifferent, or antagonistic effects, depending on drug combinations and fungal strains.
© 2022. Japanese Ophthalmological Society.

Entities:  

Keywords:  Drug susceptibility test; Filamentous fungi; Fractional inhibitory concentration (FIC) index; Fungal keratitis; Yeast-like fungi

Mesh:

Substances:

Year:  2022        PMID: 35348983     DOI: 10.1007/s10384-022-00907-2

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  38 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Synergistic interaction of miconazole and fluconazole at sub-MIC level on Candida albicans.

Authors:  Y Mikami; A Takahashi; K Yazawa; K Terao; Y Ueno
Journal:  Mycoses       Date:  1992 Nov-Dec       Impact factor: 4.377

3.  Spectrum of fungal keratitis in north China.

Authors:  Lixin Xie; Wenxian Zhong; Weiyun Shi; Shiying Sun
Journal:  Ophthalmology       Date:  2006-08-28       Impact factor: 12.079

4.  Keratomycosis: clinical and microbiologic experience with dematiaceous fungi.

Authors:  P Garg; U Gopinathan; K Choudhary; G N Rao
Journal:  Ophthalmology       Date:  2000-03       Impact factor: 12.079

5.  [Multicenter Prospective Observational Study of Fungal Keratitis--Current Status of Patients' Background, Clinical Findings, Treatment and Prognosis].

Authors:  Yoshitsugu Inoue; Yuichi Ohashi; Takashi Suzuki; Yoshikazu Shimomura; Masahiko Fukuda; Chie Sotozono; Hiroshi Hatano; Hiroshi Eguchi; Kaoru Araki-Sasaki; Saichi Hoshi; Atsuko Sunada; Seishi Asari; Takashi Yaguchi; Koichi Makimura; Shunji Yokokura; Kiyofumi Mochizuki; Yu Monden; Ryohei Nejima
Journal:  Nippon Ganka Gakkai Zasshi       Date:  2016-01

6.  In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients.

Authors:  Li Li; Zhiqun Wang; Ran Li; Shiyun Luo; Xuguang Sun
Journal:  Am J Ophthalmol       Date:  2008-08-15       Impact factor: 5.258

7.  Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium.

Authors:  Tatiana B Spader; Tarcieli P Venturini; Luana Rossato; Laura B Denardi; Patricia B Cavalheiro; Sonia A Botton; Janio M Santurio; Sydney Hartz Alves
Journal:  Rev Iberoam Micol       Date:  2013-02-09       Impact factor: 1.044

8.  In vitro combinations of natamycin with voriconazole, itraconazole and micafungin against clinical Fusarium strains causing keratitis.

Authors:  Abdullah M S Al-Hatmi; Joseph Meletiadis; Ilse Curfs-Breuker; Alexandro Bonifaz; Jacques F Meis; G Sybren De Hoog
Journal:  J Antimicrob Chemother       Date:  2015-12-24       Impact factor: 5.790

9.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

10.  In vitro synergy of natamycin and voriconazole against clinical isolates of Fusarium, Candida, Aspergillus and Curvularia spp.

Authors:  Swatishree Sradhanjali; Bandana Yein; Savitri Sharma; Sujata Das
Journal:  Br J Ophthalmol       Date:  2017-10-05       Impact factor: 4.638

View more
  1 in total

1.  Multicenter prospective observational study of fungal keratitis in Japan: analyses of culture-positive cases.

Authors:  Yoshitsugu Inoue; Yuichi Ohashi; Yoshikazu Shimomura; Chie Sotozono; Hiroshi Hatano; Masahiko Fukuda; Hiroshi Eguchi; Kaoru Araki-Sasaki; Takashi Suzuki; Saichi Hoshi; Seishi Asari; Atsuko Sunada; Keigo Kimura; Takashi Yaguchi; Koichi Makimura
Journal:  Jpn J Ophthalmol       Date:  2022-03-29       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.